DermTech Inc Equity-NMS: DMTK

Healthcare

Diagnostics & Research

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$5.4

52W high :

$16.33

1Y :

-89.18%

5Y :

-64.17%

Shares O/S :

30.21 M

Market cap :

163.16 M

What is the share price of DermTech Inc today?

DermTech Inc (DMTK) share price as of October 12, 2022, is $3.485. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of DermTech Inc?

Yes, Indian Investors can invest in the DermTech Inc (DMTK) Share by opening an international trading account with Angel One.

How can I purchase DermTech Inc shares in India?

Purchasing DermTech Inc (DMTK) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying DermTech Inc (DMTK) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of DermTech Inc?

Yes, you can purchase fractional shares of DermTech Inc (DMTK) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of DermTech Inc?

The market capitalization of DermTech Inc on February 1, 2023, is $104.69 M.

In which sector DermTech Inc belongs?

DermTech Inc operates in the Healthcare sector, specifically in the Diagnostics & Research industry.

What documents are required to invest in DermTech Inc stocks?

In order to invest in DermTech Inc (DMTK) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

DermTech, Inc. is a molecular diagnostics company. The Company is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. It provides the Pigmented Lesion Assay (PLA), which is a gene expression test that enables early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The Company offers the Nevome test, which is an adjunctive reflex test for the PLA and is used with histopathology to identify additional risk factors for melanoma and confirm the diagnosis. Its Adhesive Skin Sample Collection Kit offers properties of the adhesive and a collection of informative cellular materials for its PLA. The Company’s Telemedicine Option for the PLA is the provision of health-related services and information through electronic information and telecommunication technologies.